Voyager Therapeutics is expected to report Q2 2026 revenue of $4.52 million and an EPS loss of $0.55, with its $3.12 share price currently trading significantly below the $16.50 average analyst price target.
Investors are primarily focused on the company's "Year of Tau" Alzheimer's clinical roadmap, specifically for the gene therapy candidate VY1706 and the antibody VY7523.
Management has maintained that the IND application for VY1706 is on track for the second half of 2026, which would trigger further clinical development milestones. With a cash runway extending into 2028, the market will look for updates regarding strategic collaborations and the timing of upcoming PET imaging efficacy data.